Drug Trial Radar · NCT05036473
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 25, 2021
Primary completion
Dec 28, 2022
Study completion Dec 28, 2022
Sponsor
- Lead sponsor
- Shanghai WD Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.
Conditions
- Parkinson Disease
Interventions
WD-1603 Carbidopa-Levodopa Extended-Release TabletsDrug
Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
PlaceboDrug
placebo tablets-matching the active groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.Time frame: 27 days- from the baseline to the 27th day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.